Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mereo BioPharma Group (MREO) Invested Capital: 2020-2025

Historic Invested Capital for Mereo BioPharma Group (MREO) over the last 2 years, with Sep 2025 value amounting to $46.6 million.

  • Mereo BioPharma Group's Invested Capital fell 35.76% to $46.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.6 million, marking a year-over-year decrease of 35.76%. This contributed to the annual value of $61.0 million for FY2024, which is 20.64% up from last year.
  • Latest data reveals that Mereo BioPharma Group reported Invested Capital of $46.6 million as of Q3 2025, which was down 13.99% from $54.2 million recorded in Q2 2025.
  • In the past 5 years, Mereo BioPharma Group's Invested Capital ranged from a high of $78.7 million in Q2 2024 and a low of $18.6 million during Q2 2021.
  • For the 3-year period, Mereo BioPharma Group's Invested Capital averaged around $58.3 million, with its median value being $57.1 million (2025).
  • Over the last 5 years, Mereo BioPharma Group's Invested Capital had its largest YoY gain of 118.76% in 2021, and its largest YoY loss of 87.84% in 2021.
  • Over the past 5 years, Mereo BioPharma Group's Invested Capital (Quarterly) stood at $36.5 million in 2021, then skyrocketed by 41.99% to $51.9 million in 2022, then decreased by 2.60% to $50.5 million in 2023, then grew by 20.64% to $61.0 million in 2024, then tumbled by 35.76% to $46.6 million in 2025.
  • Its Invested Capital was $46.6 million in Q3 2025, compared to $54.2 million in Q2 2025 and $60.1 million in Q1 2025.